Language:

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

The New England journal of medicine, 2017-05, Vol.376 (18), p.1713-1722 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;info:eu-repo/semantics/openAccess ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1615664 ;PMID: 28304224

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Author: Sabatine, Marc S ; Giugliano, Robert P ; Keech, Anthony C ; Honarpour, Narimon ; Wiviott, Stephen D ; Murphy, Sabina A ; Kuder, Julia F ; Wang, Huei ; Liu, Thomas ; Wasserman, Scott M ; Sever, Peter S ; Pedersen, Terje R
Subjects: Aged ; Analysis ; Antibodies, Monoclonal ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Anticholesteremic Agents ; Anticholesteremic Agents - adverse effects ; Anticholesteremic Agents - therapeutic use ; Atherosclerosis ; Atherosclerosis - drug therapy ; Cardiovascular & respiratory systems ; Cardiovascular disease ; Cardiovascular Diseases ; Cardiovascular Diseases - complications ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - mortality ; Cholesterol ; Cholesterol, LDL ; Cholesterol, LDL - blood ; Clinical outcomes ; Double-Blind Method ; Drug dosages ; Drug therapy ; Drug Therapy, Combination ; Endocrinologie, métabolisme & nutrition ; Endocrinology, metabolism & nutrition ; Female ; Follow-Up Studies ; Human health and pathology ; Human health sciences ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypercholesterolemia ; Hypercholesterolemia - complications ; Hypercholesterolemia - drug therapy ; Incidence ; Least-Squares Analysis ; Life Sciences ; Low density lipoprotein ; Male ; Middle Aged ; Monoclonal antibodies ; Patients ; PCSK9 Inhibitors ; PCSK9 protein, human ; Pharmacie, pharmacologie & toxicologie ; Pharmacy, pharmacology & toxicology ; Prevention ; Proprotein Convertase 9 ; Proprotein convertases ; Sciences de la santé humaine ; Statins ; Stroke ; Systèmes cardiovasculaire & respiratoire ; Treatment outcome
Is Part Of: The New England journal of medicine, 2017-05, Vol.376 (18), p.1713-1722
Description: In this trial, 27,564 patients with cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter or higher on statin therapy were assigned to either evolocumab or placebo. At 2.2 years, the evolocumab group had a significantly lower rate of major adverse cardiovascular events. Low-density lipoprotein (LDL) cholesterol is a well-established and modifiable risk factor for cardiovascular disease. Monoclonal antibodies that inhibit proprotein convertase subtilisin–kexin type 9 (PCSK9) have emerged as a new class of drugs that effectively lower LDL cholesterol levels. 1 Evolocumab, a member of this class, is a fully human monoclonal antibody that reduces LDL cholesterol levels by approximately 60%. 2 – 6 Genetic studies have shown that carriage of PCSK9 loss-of-function alleles is associated with lower LDL cholesterol levels and a reduced risk of myocardial infarction. 7 , 8 Moreover, exploratory data from longer-term follow-up in phase 2 and phase 3 trials of PCSK9 inhibitors . . .
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
ISSN: 1533-4406
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1615664
PMID: 28304224
Source: MEDLINE
NORA Norwegian Open Research Archives
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;info:eu-repo/semantics/openAccess ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1615664 ;PMID: 28304224

Searching Remote Databases, Please Wait